



## Protagonist Therapeutics to Participate in the SVB Leerink Virtual 10th Annual Global Healthcare Conference

February 16, 2021

NEWARK, Calif., Feb. 16, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at SVB Leerink Virtual 10th Annual Global Healthcare Conference taking place February 22 to February 26, 2021.

---

### Fireside chat details:

Date: Wednesday, February 24, 2021


Time: 10:40 a.m. EST

A live and archived webcast of the event will be available at <https://wsw.com/webcast/svbleerink47/ptgx/2693120> and on the Investors section of the Protagonist Therapeutics website at <http://investors.protagonist-inc.com/>.

### About Protagonist Therapeutics, Inc.

Protagonist Therapeutics is a clinical stage biopharmaceutical company with multiple peptide-based new chemical entities in different stages of development. PTG-300 is an injectable hepcidin mimetic in a Phase 2 proof-of-concept clinical trial for polycythemia vera, and a separate Phase 2 clinical study for hereditary hemochromatosis. PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in a Phase 2 clinical trial for Crohn's disease. Two additional oral peptide interleukin-23 receptor antagonist candidates are in development: PN-235, in a Phase 1 study, and PN-232, in the late preclinical stage. PN-943 is an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in a Phase 2 study for the potential treatment of inflammatory bowel disease, with ulcerative colitis as the initial targeted indication. The Company utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms.

Protagonist is headquartered in Newark, California. For further information, please visit <http://www.protagonist-inc.com>.

 View original content to download multimedia: <http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-participate-in-the-svb-leerink-virtual-10th-annual-global-healthcare-conference-301227755.html>

SOURCE Protagonist Therapeutics, Inc.

Investor Relations: Brian Korb, Solebury Trout, Tel: + 1 646-378-2923, Email: [bkorb@soleburytrout.com](mailto:bkorb@soleburytrout.com) or Media: Courtney Solberg, Solebury Trout, Tel: +1 917-698-9253, Email: [csolberg@soleburytrout.com](mailto:csolberg@soleburytrout.com)